KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $550.6 million.

  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity fell 3.97% to $527.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 2.43%. This contributed to the annual value of $550.6 million for FY2024, which is 0.47% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Liabilities and Shareholders Equity of $550.6 million as of FY2024, which was up 0.47% from $548.1 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $550.6 million during FY2024, with a 5-year trough of $463.7 million in FY2020.
  • In the last 3 years, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $548.1 million in 2023 and averaged $523.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 42.97% in 2020, then declined by 13.34% in 2022.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Liabilities and Shareholders Equity stood at $463.7 million in 2020, then rose by 17.19% to $543.4 million in 2021, then decreased by 13.34% to $470.9 million in 2022, then rose by 16.40% to $548.1 million in 2023, then increased by 0.47% to $550.6 million in 2024.